Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AR-301 (tosatoxumab) in ventilator-associated pneumonia due to Staphylococcus aureus
2017-004339-35Phase 3Completed
- Sponsor
- Aridis Pharmaceuticals, Inc.
- Start
- Dec 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of tosatoxumab in ventilator-associated pneumonia (VAP), staphylococcal pneumonia, sponsored by Aridis Pharmaceuticals, Inc.. Started Dec 2018; status: completed.
02
Drugs
tosatoxumab
03
Conditions
ventilator-associated pneumonia (VAP)staphylococcal pneumonia
Beyond the preview
Go deeper on 2017-004339-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004339-35.